ZTS Stock: Zoetis Inc. Stock Price, Analysis & Insights
Get live zts stock price $119.79, comprehensive Zoetis Inc. stock analysis, charts, news, and expert forecast. Real-time zts stock data and investment insights.
Loading chart...
Company Overview
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Company Information
- CEO
- Kristin C. Peck
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 13800
Contact Information
- Website
- https://www.zoetis.com
- Address
- 10 Sylvan Way
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 20.2)
Business Model & Strategy
Zoetis Inc. operates in the Drug Manufacturers - Specialty & Generic industry, focusing on medical services, pharmaceutical development, and healthcare delivery. As a mid-cap company, Zoetis Inc. benefits from scale advantages, market presence, and established operations. Under the leadership of CEO Kristin C. Peck, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Drug Manufacturers - Specialty & Generic model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Zoetis Inc. competes in the Drug Manufacturers - Specialty & Generic within the broader Healthcare. With 52.8 billion in market capitalization, the company is positioned as a established player in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the New York Stock Exchange, Zoetis Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Zoetis Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Zoetis Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Zoetis Inc.
- ⚠Investors should consider how Zoetis Inc. fits within their overall portfolio allocation
Market Cap
52.79B
P/E Ratio
20.17
Beta
0.96
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 52.79B market capitalization
- Trading Volume: 170.23K shares traded today
- Price Range: 52-week range of $117.26 - $181.85
- Exchange: Listed on New York Stock Exchange
Financial Metrics
Market Analysis for Zoetis Inc.
Zoetis Inc. (ZTS) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. With a current market capitalization of 52.79B, the company represents a significant player in its market. The stock is currently trading at $119.79 with a negativedaily change of 0.37%.
The company's 13800 employee base and presence on the New York Stock Exchangeexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 20.17, beta of 0.96, and 52-week price range from $117.26 to $181.85when evaluating investment opportunities.
Why Invest in Zoetis Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (New York Stock Exchange)
- • Experienced leadership under Kristin C. Peck
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.